Epithelial High Grade Serous Ovarian Cancer
Conditions
Keywords
immune microenvironment, CD8+ T cells, plasma cells, Tertiary lymphoid structures
Brief summary
The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with carboplatin/paclitaxel chemotherapy.
Interventions
OTHERAssessment of elements of adaptive immunity in tumor biopsies
Tertiary lymphoid structures, Plasma cells, p53 and CD8+ T cells will be evaluated at tumor biopsies of patients with advanced ovarian cancer treated with chemotherapy.
Sponsors
Hellenic Cooperative Oncology Group
Attikon Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* Patients with advanced high grade serous ovarian cancer treated with carboplatin/paclitaxel chemotherapy
Exclusion criteria
* Any other histology than high grade ovarian cancer * Patients with stages I-II (based on FIGO staging)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of: Tertiary Lymphoid Structures (presence, absence) in tumor biopsies | through study completion, an average of 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Plasma cells (4-tiered score) | 3- years time frame (upon study completion) |
| PD-L1 score (TPS score) in tumor biopsies | upon study completion (3 years) |
| CD8 cells (low : <5 cells/HPF vs high (> 5 cells/HPF) expression) in tumor biopsies | upron study completion (3 years) |
| p53 (presence, absence) in tumor biopsies (immunohistochemistry) | upon study compeltion (3 years) |
Countries
Greece
Outcome results
None listed